JAZZ. Media: Jacqueline Kirby Jazz Pharmaceuticals plc. Investor Relations Jazz Pharmaceuticals PLC . . Katherine Littrell - Vice President, Investor Relations. Media: Kristin Bhavnani Head of Global Corporate Communications DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on . InvestorInfo@jazzpharma.com. Today, Jazz . Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families . Jazz Pharmaceuticals plc [email protected] Ireland +353 1 637 2141 U.S. +1 215 867 4948. The transaction is expected to close in the third quarter of 2018 and is subject . Jazz Pharmaceuticals and . At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Learn about Jazz Pharmaceuticals PLC (JAZZ:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock . The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement . Ireland +353 1 634 3211. At Jazz, our purpose is to innovate to transform the lives of patients and their families. investorinfo@jazzpharma.com Ireland: +353 1 634 7892 U.S.: +1 650 496 2800. Jazz Pharmaceuticals PLC ( JAZZ 1.34%) Q1 2021 Earnings Call May 4, 2021, 4:30 p.m. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute . Asparaginase-associated toxicity in children . Morningstar Rating. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. Contents: Prepared Remarks; . Investor Home. Jazz Pharmaceuticals Contacts: Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2019 Results Earnings Conference Call November 5, 2019 4:30 PM ETCompany Participants. Jazz Investor Contact: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 . Jun 01, 2022, 4:15 PM ET. Investor and Media Overview. Investor Relations Jazz Pharmaceuticals PLC JAZZ Morningstar Rating Rating as of Mar 4, 2022. Press Releases . We are focused on developing life-changing medicines for people with serious diseases often with limited or no options so they can live their lives more fully. This page shows recent SEC filings related to Jazz Pharmaceuticals PLC. Head of Investor Relations at Jazz Pharmaceuticals. DUBLIN, May 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2022 Global Healthcare Conference on Tuesday, May 10, 2022, at 12:40 p.m. PT / 3:40 p.m. Innovating to Transform the Lives of Those with Sleep Disorders. It's been a good week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders, because the company has just released its latest yearly results, and the shares gained 7.4% to US$171. Corporate - Footer Links 1. Print. . Key statistics for lung cancer. Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ETCompany Participants. Media: Jacqueline Kirby Vice President, . Asparaginase-associated toxicity in children with . PR Newswire. The specialty pharmaceutical company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.13. DUBLIN, April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: . . DUBLIN, June 7, 2022-- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) . ET / 8:40 p.m. IST in Las Vegas. DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc . Thank . Corporate Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Q3 2021 Earnings Call Nov 9, 2021, 4:30 p.m. Media: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc . References. Jazz Pharmaceuticals PLC - Stock Analysis. 1-866-398-0833. Jazz Pharmaceuticals plc. ET. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)-- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced results from the recently completed Phase 1 clinical study of JZP-386, a deuterium-containing analog of sodium oxybate. Jazz Pharmaceuticals plc JAZZ is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. ET / 7:00 p.m. IST in New York.. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . Jazz Pharmaceuticals plc. Printed . Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. InvestorInfo@jazzpharma.com. [Operator instructions] As a reminder, this conference call is being recorded. Supernus Pharmaceuticals, Inc. 9715 Key West Avenue. ET / 7:15 - 7:55 p.m. GMT.. A live audio webcast of the presentation may be accessed from the Investors section . We are dedicated to developing life-changing medicines for people with serious diseasesoften with limited or no therapeutic options. Andrea Flynn - Investor Relations. ET. DUBLIN, Oct. 26, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that it will report its 2021 third quarter financial results on Tuesday, November 9, 2021 after the close of the. Our current lead drug candidate, FT218, is . head of investor relations . I will now turn the call over to Andrea Flynn, Head Investor Relations at Jazz Pharmaceuticals. Aug 13, 2021 7:07AM EDT. About Jazz Pharmaceuticals plc . Investors News Releases ET / 7:00 p.m. IST in New York.. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . Jazz Pharmaceuticals PLC (JAZZ) CEO Bruce Cozadd on Q3 2021 Results - Earnings Call Transcript. . . Jazz Pharmaceuticals PLC's Company Profile. Vice President, Head, Investor Relations. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . Consensus estimates suggest investors . Investors: Andrea N. Flynn, Ph.D.Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211. Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 . InvestorInfo@jazzpharma.com. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Welcome to the Jazz Pharmaceuticals plc second-quarter 2019 earnings conference call. Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and . . We are dedicated to developing life-changing . [Operator instructions] I will now turn the call over to Kathee Littrell, head of investor relations at Jazz . Jazz Pharmaceuticals PLC (JAZZ 0.48%) Q4 2020 Earnings Call Feb 23, 2021, 4:30 p.m. The Investor Relations website contains information about Jazz Pharmaceuticals plc's business for stockholders, potential investors, and financial analysts. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211. Investor Relations Jazz . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 . VP & Head of Investor Relations: N/A: N/A: N/A: Ms. Neena M. Patil J.D. Investor Relations. ET. The presentation will be available to registered conference attendees. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. SA Transcripts Tue, Nov. 09, 2021. Ireland +353 1 634 . About Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the . Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products . Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Jazz Pharmaceuticals PLC - Stock Analysis JAZZ. SUPN Stock Price Today by TradingView. . Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Jazz Pharmaceuticals plc . DUBLIN, Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced Bruce Cozadd, chairman and chief executive officer, will present virtually as part of the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, from 2:15 - 2:55 p.m. Jazz Pharmaceuticals plc (NASDAQ:NASDAQ:JAZZ) Q4 2020 Earnings Conference Call February 23, 2021 04:30 PM ET Company Participants Andrea Flynn - Head of Investor Relations Bruce Cozadd -. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. Skip to main navigation Top Bar Nav Contact Us. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Ireland +353 1 634 3211. Bruce . Media: Kristin Bhavnani Head of Global Corporate . Home; . Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. Business Description. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211 U.S. +1 650 496 2717. Rating as of May 6, 2022. Media: Kristin Bhavnani Head of Global Corporate Communications Thank you, and good afternoon, everyone. About Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the . 1 Hijiya N, van der Sluis IM. JAZZ earnings call for the period ending September 30, 2021. Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email . Learn about Jazz Pharmaceuticals PLC (JAZZ:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock . ET / 7:00 p.m. IST in New York.. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy . Media: Kristin Bhavnani Head of Global Corporate . Bruce Cozadd - Chairman and Chief . | May 24, 2022 . Investor Relations. Review quarterly and annual revenue, net income, and cash flow for Jazz Pharmaceuticals PLC (JAZZ:XMEX) stock through the last fiscal year. DUBLIN, Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences: . DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) . Social Icons . Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Vice President, Head, Investor Relations. By transforming biopharmaceutical discoveries into . . Supernus Support. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Wednesday, May, 4th. Provided by PR Newswire May 4, 2022 1:10 PM PDT. Cantor Virtual Global Healthcare Conference on Monday . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland, +353 1 634 3211 U.S., +1 650 496 2717. You may begin. DUBLIN, July 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 second quarter financia. Quote Stock Analysis News Price vs Fair Value . Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious . Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Jazz Investor Contact: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 . and Investor Relations 781.674.5284 ir@concertpharma.com. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement . Investor Relations. Quote Stock Analysis News Price vs Fair Value Sustainability Trailing Returns Financials . Investor and Media Overview. We'd be surprised if Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders haven't noticed that an insider, Elmar Schnee, recently sold US$251k worth of stock at US$154 per . ET. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. References. Media Contact: Kristin Bhavnani Head of . Nov 9, 2021, 4:30 p.m. References: American Cancer Society. Vice President, Head, Investor Relations. Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Revenues came . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Our decades of proven success come from passionate team members around the globe collaborating to bring the . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Rockville, MD 20850 (301) 838-2500. info@supernus.com. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland, +353 1 634 3211. Media: Kristin Bhavnani Head of Global Corporate . Events and Presentations . Jazz Pharmaceuticals PLC ( JAZZ -2.04%) Q3 2021 Earnings Call. . . Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, . JAZZ Jazz Pharmaceuticals PLC Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance. 1 Hijiya N, van der Sluis IM. Ms. Andrea N. Flynn Ph.D., VP & Head of Investor Relations; Ms. Neena M. Patil J.D., Chief Legal . Contents: Prepared Remarks; . We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. Welcome to the Jazz Pharmaceuticals plc first-quarter 2019 earnings conference call. Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211. In the coming days, we are showcasing our ongoing commitment to the sleep community with our presence at SLEEP 2022, the 36 th annual meeting of the Associated Professional Sleep Societies. Image source: The Motley Fool. The Investor Relations website contains information about Jazz Pharmaceuticals plc's business for stockholders, potential investors, and financial analysts. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. BofA Virtual Global Healthcare Conference 2021 on Wednesday, September 15, 2021 . Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. DUBLIN, June 29, 2018 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a definitive agreement to sell its rights related to Prialt (ziconotide) intrathecal infusion to TerSera Therapeutics LLC (TerSera) for $80 million in cash at closing. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Investor Relations.